NASDAQ:VXRTVaxart Stock Price, Forecast & News

Vaxart's stock was trading at $2.07 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, VXRT shares have increased by 29.5% and is now trading at $2.68. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Vaxart.

Vaxart is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Vaxart.

Vaxart Inc (NASDAQ:VXRT) issued its quarterly earnings data on Tuesday, May, 12th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.04) by $0.02. The biotechnology company had revenue of $2.90 million for the quarter, compared to analyst estimates of $2.80 million. Vaxart had a negative net margin of 252.86% and a negative return on equity of 94.20%. View Vaxart's earnings history.

Vaxart shares reverse split before market open on Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 13th 2018. An investor that had 100 shares of Vaxart stock prior to the reverse split would have 9 shares after the split.

2 brokerages have issued 12 month target prices for Vaxart's stock. Their forecasts range from $6.00 to $7.00. On average, they anticipate Vaxart's stock price to reach $6.50 in the next year. This suggests a possible upside of 142.5% from the stock's current price. View analysts' price targets for Vaxart.

Headlines about VXRT stock have been trending somewhat negative this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Vaxart earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutVaxart.

Some companies that are related to Vaxart include Cellectis (CLLS), BioCryst Pharmaceuticals (BCRX), Avrobio (AVRO), Replimune Group (REPL), AVITA MED LTD/S (RCEL), Atara Biotherapeutics (ATRA), Aerie Pharmaceuticals (AERI), Osiris Therapeutics (OSIR), AVITA MED LTD/S (AVMXY), Nantkwest (NK), Vericel (VCEL), Adaptimmune Therapeutics (ADAP), Oyster Point Pharma (OYST), Prevail Therapeutics (PRVL) and Aptose Biosciences (APTO). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxart investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), VBI Vaccines (VBIV), Conatus Pharmaceuticals (CNAT), Crispr Therapeutics (CRSP), Advanced Micro Devices (AMD), Johnson & Johnson (JNJ), Agile Therapeutics (AGRX) and Co-Diagnostics (CODX).

Vaxart trades on the NASDAQ under the ticker symbol "VXRT."

Vaxart's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (0.73%), Hussman Strategic Advisors Inc. (0.71%), Geode Capital Management LLC (0.48%), Harvest Investment Services LLC (0.07%), Bank of New York Mellon Corp (0.06%) and Strategic Wealth Management Group LLC (0.02%). Company insiders that own Vaxart stock include Armistice Capital Master Fund, Armistice Capital, Llc, John P Richard, Michael J Finney, Sean Tucker, Todd C Davis and Wouter Latour. View institutional ownership trends for Vaxart.

VXRT stock was purchased by a variety of institutional investors in the last quarter, including Hussman Strategic Advisors Inc., BlackRock Inc., Geode Capital Management LLC, Harvest Investment Services LLC, Bank of New York Mellon Corp, and Strategic Wealth Management Group LLC. Company insiders that have bought Vaxart stock in the last two years include Armistice Capital Master Fund, John P Richard, Michael J Finney, Sean Tucker, and Wouter Latour. View insider buying and selling activity for Vaxart.

Shares of VXRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VXRT stock can currently be purchased for approximately $2.68.

Vaxart has a market capitalization of $198.80 million and generates $9.86 million in revenue each year. The biotechnology company earns $-18,650,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. Vaxart employs 34 workers across the globe.

The official website for Vaxart is www.vaxart.com.

Vaxart's mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 650-550-3500 or via email at [email protected]